RxDoctor Payments Data
★ My doctorsLook up a doctor →

Stephen Krieger, MD

Neurology · New York, NYNPI 1417023367

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.6%. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,135,901in general payments, 2019–2025

Across 727 payments — averaging $1562.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$256K
  • Biogen$214K
  • TG Therapeutics, Inc.$167K
  • EMD Serono, Inc.$153K
  • Genentech, Inc.$97K
  • Novartis$96K
  • plus $152K from 18 others
$2,118,872in research payments, 2019–2025

Across 96 payments — averaging $22,072 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$1.1M
  • Bristol Myers Squibb$654K
  • Novartis$211K
  • EMD Serono Research & Development Institute, Inc.$119K
  • TG Therapeutics, Inc.$26K
  • Jazz Pharmaceuticals Inc.$18K
  • plus $12K from 2 others

What the payments were for

  • Consulting fees$376,34333%
  • Speaking & faculty fees$626,63855%
  • Travel & lodging$111,71810%
  • Food & beverage$20,9072%
  • Education$2950%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech USA, Inc.129$256,261
Biogen154$214,327
TG Therapeutics, Inc.107$166,735
EMD Serono, Inc.133$153,459
Genentech, Inc.36$96,861
Novartis86$96,227
Sanofi31$55,287
Novartis Pharma AG7$20,960
F. Hoffmann-la Roche AG9$15,876
Cycle Pharmaceuticals Inc6$14,561
EMD Serono Research & Development Institute, Inc.1$12,677
Merck Kgaa5$12,292
Sanofi US Services Inc.3$11,896
Merck Serono S.p.a.1$2,120
Mallinckrodt Enterprises LLC1$2,100
Janssen Scientific Affairs, LLC1$1,320
PTC Therapeutics, Inc.2$1,153
Banner Life Sciences, LLC1$900
Bristol Myers Squibb8$457
Acorda Therapeutics, Inc2$259
E.r. Squibb & Sons, L.L.C.1$85
Teva Pharmaceuticals USA, Inc.1$35
AstraZeneca1$31
Jazz Pharmaceuticals Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,135,901 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York →

Medicare billing

Part B allowed, 2024
$23,501
Medicare patients
76
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dalfampridine ErDalfampridine16$5,539
Baclofen24$683
Gabapentin18$260
Pregabalin11$245

Paid to pharmacies, not to this prescriber.

Other neurology in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →